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IMPORTANCE Tumor-treating fields (TTFields) is an antimitotic treatment modality that
interferes with glioblastoma cell division and organelle assembly by delivering low-intensity
alternating electric fields to the tumor.
OBJECTIVE To investigate whether TTFields improves progression-free and overall survival of
patients with glioblastoma, a fatal disease that commonly recurs at the initial tumor site or in
the central nervous system.
DESIGN, SETTING, AND PARTICIPANTS In this randomized, open-label trial, 695 patientswith
glioblastomawhose tumorwas resected or biopsied and had completed concomitant
radiochemotherapy (median time fromdiagnosis to randomization, 3.8months) were enrolled
at 83 centers (July 2009-2014) and followed up throughDecember 2016. A preliminary report
from this trial was published in 2015; this report describes the final analysis.
INTERVENTIONS Patients were randomized 2:1 to TTFields plus maintenance temozolomide
chemotherapy (n = 466) or temozolomide alone (n = 229). The TTFields, consisting of
low-intensity, 200 kHz frequency, alternating electric fields, was delivered ( 18 hours/d) via
4 transducer arrays on the shaved scalp and connected to a portable device. Temozolomide
was administered to both groups (150-200mg/m2) for 5 days per 28-day cycle (6-12 cycles).
MAIN OUTCOMES ANDMEASURES Progression-free survival (tested at α = .046). The
secondary end point was overall survival (tested hierarchically at α = .048). Analyses were
performed for the intent-to-treat population. Adverse events were compared by group.
RESULTS Of the 695 randomized patients (median age, 56 years; IQR, 48-63; 473men [68%]),
637 (92%) completed the trial. Median progression-free survival from randomizationwas 6.7
months in the TTFields-temozolomide group and 4.0months in the temozolomide-alone group
(HR, 0.63; 95%CI, 0.52-0.76; P < .001). Median overall survival was 20.9months in the
TTFields-temozolomide group vs 16.0months in the temozolomide-alone group (HR, 0.63;
95%CI, 0.53-0.76; P < .001). Systemic adverse event frequencywas 48% in the
TTFields-temozolomide group and 44% in the temozolomide-alone group.Mild tomoderate
skin toxicity underneath the transducer arrays occurred in 52%of patients who received
TTFields-temozolomide vs no patients who received temozolomide alone.
CONCLUSIONS AND RELEVANCE In the final analysis of this randomized clinical trial of patients
with glioblastomawho had received standard radiochemotherapy, the addition of TTFields to
maintenance temozolomide chemotherapy vs maintenance temozolomide alone, resulted in
statistically significant improvement in progression-free survival and overall survival. These
results are consistent with the previous interim analysis.
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G lioblastoma is the most common and aggressive pri-marybrain tumorwith anannual incidenceof 3.19per100000.1-5 The disease course is typically rapid,with
only approximately 1 in 4 patients alive 2 years after diagno-
sis, and only 5% to 10% of patients alive at 5 years.1,6,7
Since the current standard of care was established, con-
sisting of surgical resection or biopsy, followed by radio-
therapy with concomitant temozolomide chemotherapy,
followed bymaintenance temozolomide for 6 to 12 months,6
little progress has been made in the treatment of this
disease.3,8,9 Most trials have shownmedian progression-free
survival andmedian overall survival from diagnosis of 6.2 to
7.5 months and 14.6 to 16.7 months, respectively.4-6,8
Tumor-treating fields (TTFields) are an antimitotic treat-
ment that selectively affects dividing glioblastoma cells by
delivering low-intensity, intermediate-frequency (200 kHz)
alternating electric fields via transducer arrays applied to the
scalp.10,11 Tumor-treating fields causemitotic arrest andapop-
tosis of rapidly dividing cells.10,11 Preclinical studies demon-
strated increased sensitivity to chemotherapy with the addi-
tion of TTFields in human glioblastoma cell lines and in
animal tumormodels.12 In a randomized phase 3 trial involv-
ing 237 patients with recurrent glioblastoma whose several
lines of prior therapy had failed, TTFields monotherapy
was compared with the treating physicians’ best choice of
salvage chemotherapy. Although no survival difference was
observed, the higher objective response rate (12%vs 7%) sug-
gested single-modality activity of TTFields.13
In 2009, this randomized phase 3 clinical trial was initi-
ated, comparing maintenance temozolomide alone with
maintenance temozolomide in combination with TTFields
among patients with glioblastoma. A preplanned interim
analysis involving the first 315 patients randomized was pre-
viously reported and demonstrated improved progression-
free and overall survival.14 This article reports the final
analysis involving all 695 randomized patients, with a
median follow-up of 40 months and a minimum follow-up
of 24 months.
Methods
The studywas approved by the institutional reviewboards or
ethics committees of all participating centers, and all pa-
tients providedwritten informed consent before entering the
study. The trial protocol and statistical analysis plan are
included in Supplement 1.
Study Population
Patients eligible for this studywere aged 18years or older, had
a Karnofsky performance score of 70 or higher (a score of ≥70
ensures independence in activities of daily living), and had
newly diagnosed andhistologically confirmed supratentorial
glioblastoma (World Health Organization [WHO] grade IV
astrocytoma15). All participants had undergonemaximal safe
debulking surgery when feasible or biopsy and had com-
pleted standard radiotherapy with concomitant temozolo-
mide at the time of enrollment. Prior use of implanted
carmustine wafers was allowed. Patients with evidence of
progressive disease following radiochemotherapy, infraten-
torial tumor location, and severe comorbidities were ex-
cluded. Adequate hematological, liver, and kidney function
tests to allow for temozolomide chemotherapy were
required.6,14,16
Study Design and Treatment
Thismulticenter, open-label, randomizedclinicalphase3 trial,
recruited695patients at83 sites inNorthAmerica,Europe, the
Republic ofKorea, and Israel. The trialwasdesigned to test the
efficacy and safety of TTFields in combinationwith best stan-
dardof care in the treatmentofnewlydiagnosedglioblastoma.
Patientswere randomizedafter theendof radiochemotherapy
at a ratioof 2:1 to receive standardmaintenance temozolomide
chemotherapy (150-200mg/m2/d for 5 days every 28 days for
6cycles)withorwithout theadditionofTTFields.Tumor treat-
ing fields treatmentwas tobe initiated at least 4weeksbutnot
more than 7weeks from the last day of radiotherapy.Mainte-
nance temozolomidewasdelivered in28-daycycles according
to the protocol established by the European Organisation for
Research and Treatment of Cancer (EORTC) Brain Tumor and
Radiotherapy Groups and the National Cancer Institute of
Canada (NCIC)ClinicalTrialsGroup.6Extensionof theduration
ofmaintenancetemozolomidebeyond6cycleswasallowedper
local practice. Randomization was performed using a central
web-based randomization systemandwas stratifiedbyextent
of resection (biopsy,partial resection,gross total resection)and
by the methylation status of the O6-methylguanine-DNA
methyltransferase (MGMT) gene promoter (methylated,
unmethylated, unknown).
Treatment with TTFields was delivered through 4 trans-
ducer arrays with 9 insulated electrodes each placed on the
shaved scalp and connected to a portable device set to gener-
ate200-kHzelectric fieldswithin thebrain (Optune,Novocure
Inc).Transducerarray layoutsweredeterminedusingaTTFields
mappingsoftware systemtooptimize field intensitywithin the
treated tumor (NovoTAL,Novocure Inc). Patientswere trained
by thenursingstaff anddevice technician tooperate thedevice
independently, replace transducerarrays,andtroubleshootany
Key Points
Question Does the use of tumor-treating fields (TTFields),
consisting of low-intensity, alternating electric fields delivered
via transducer arrays applied to the scalp, when added to
maintenance temozolomide chemotherapy, improve
progression-free survival for patients with glioblastoma?
Findings In this randomized clinical trial involving 695 patients
with glioblastomawho had completed initial radiochemotherapy,
median progression-free survival from randomization was 6.7
months in the TTFields plus temozolomide group and 4.0months
in the temozolomide-alone group (hazard ratio, 0.63), a significant
difference.
Meaning Among patients with glioblastoma, the addition of
TTFields to maintenance temozolomide chemotherapy resulted in
statistically significant improvement in survival. These results are
consistent with those reported in a previous interim analysis.
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alarmconditions (eg, disconnected cables). All treatmentwas
delivered on an outpatient basis and at home. The transducer
arraysweresupplied in individualsterilepackages,andreplaced
by thepatient, a caregiver, or adevice technician twice aweek.
Althoughuninterrupted treatmentwas recommended, thepa-
tient could take short treatment breaks to tend to personal
needs. The patient was advised to continue treatment for no
fewer than 18 hours a day.
If tumorprogressionoccurred, second-line therapywasof-
fered per local practice. However, in the experimental group,
TTFields could be continued until second radiologic progres-
sion occurred or for a maximum of 24 months.
Patient Surveillance and Follow-up
Patientsdiagnosedwithglioblastomawhohadundergone sur-
gical resection or biopsy and had received standard radioche-
motherapywere randomized to receiveeitherTTFieldsplus te-
mozolomide or temozolomide alone between July 2009 and
December 2014 (Figure 1). The database was locked for final
analysis on December 28, 2016. Baseline contrast–enhanced
magnetic resonance imaging (MRI) of the brain was required
within 2 weeks before starting treatment with maintenance
temozolomide with or without TTFields. A complete physical
examinationand laboratoryparameterswereperformedwithin
1week of treatment start. Evaluation also included the EORTC
QLQ-C30 quality-of-life questionnaire with its brain-specific
module (BN-20)17,18andaMini-MentalStateExamination(a test
result of 27-30 points is considered normal function). Patients
were seen monthly for medical follow-up and routine labora-
toryexaminations.Qualityof lifewasassessedevery3months.
Adverse events were recorded for 2 months after treat-
ment discontinuation according to National Cancer Institute
CommonToxicityCriteria (NCI-CTC)v3.0.Adverseeventswere
presented descriptively as number and percentage of pa-
tients with each adverse event term for all patients available
at the time of the analysis.
Independent Radiological Review
Magnetic resonance imagingwas performed at 2-month inter-
valsuntilsecondprogression.Intheeventofclinicalprogression,
MRIwastobeperformedwithin1weekaftertheinvestigatorhad
becomeawareof it.AllMRIswere reviewedby2blindedcentral
independentradiologists (BioClinica Inc)andwereevaluatedfor
tumorresponseandprogression(Macdonaldcriteria19).Forcases
Figure 1. Recruitment and Inclusion of Patients in the Study
1019 Patients signed informed consent
and were assessed for eligibility
324 Excluded
82 Progressive disease prior to randomization
52 Did not meet eligibility criteriaa
53 Refused to participate (did not want
to be randomized)
46 Did not want to use the device
20 Agreed to participate in another trial
18 Lived too far away
8 Did not complete radiotherapy
4 Refused further treatment
4 Could not tolerate temozolomide
chemotherapy
37 Other reasons
695 Randomized
466 Included in the primary analysis
456 Included in the safety end point
analysis
466 Randomized to receive tumor-treating
fields therapy plus maintenance
temozolomide 
456 Received intervention as randomized
10 Did not receive intervention as
randomized (withdrew consent prior
to treatment start)
229 Randomized to receive maintenance 
temozolomide alone
216 Received intervention as randomized
13 Did not receive intervention as
randomized (withdrew consent prior
to treatment start)
229 Included in the primary analysis
216 Included in the safety end point
analysis
39 Patients lost to follow-up
25 Withdrew consent
3 Investigator decision
2 No adherence
9 Disease progression
14 Patients lost to follow-up
12 Withdrew consent
1 Investigator decision
1 Disease progression
26 Crossed over to receive tumor-treating
fields plus temozolomide following 
interim results release
a Ten patients were out of
randomization window; 8 had low
platelet counts; 17, infratentorial
disease; 4, elevated liver enzymes;
3, programmable shunts;
10, pacemakers or defibrillators.
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inwhich the2 reviewerswerenot inagreement, a thirdblinded
radiologist adjudicated between them.
CentralMGMT Testing, Pathology Review,
andMolecular Analyses
In patients with paraffin-embedded tumor tissue available,
evaluation of the MGMT methylation status was performed
using quantitative methylation-specific polymerase chain
reaction3,20 by a central laboratory licensed byMDxHealth. If
theMGMTmethylation status could not be determined cen-
trally prior to randomization, localMGMTmethylation status
wasused for stratification.All data analyseswerebasedon the
central blinded assessment.
Patients were included based on initial local histological
diagnosis. A retrospectivepathology reviewandevaluationof
molecular testingwasperformedby aneuropathologist (B.L.)
and molecular biologist (M.E.H.). Deletion of chromosomal
arms1pand19qandamplificationof theepidermalgrowth fac-
tor receptor (EGFR)were evaluated by fluorescent in situ hy-
bridization (FISH), immunohistochemistry (IHC), or both; and
the mutation status of the isocitrate dehydrogenase 1 (IDH1)
genewasdeterminedby immunohistochemistry for themost
common mutant IDH1-R132H as described previously.21 For
cases inwhich insufficient tissuewasavailable forEGFRFISH,
the result of EGFR IHCwas used as a surrogate (Hirsch score,
≥200 amplified; <200, not amplified).22
Outcomes
Primary and Secondary End Points
Theprimary endpointwas progression-free survival, and the
secondary end point was overall survival, with analyses con-
ducted in the intent-to-treat population.
The protocol defined that overall survival would be ana-
lyzed inaper-protocolpopulation includingonlypatientswho
received their original allocated treatments. However, 26 pa-
tients (11%) in the temozolomide-alone control group crossed
over and receivedTTFields afterDecember2014, following re-
lease of the results of the interim analysis of the trial. These
26 patients had more favorable baseline characteristics than
the rest of the control patients (MGMT methylated, 48%;
Karnofsky performance score, 80-100; time from end of ra-
diotherapytorandomization,31days)andreceivedmorecycles
of temozolomide (median, 10.5 cycles). Toavoidpossible bias,
these patients were analyzed as randomized in the control
group according to the intent-to-treat principle.
Exploratory End Points
Other predefined exploratory end points were percentage of
patientsaliveandprogression freeat6months, annualizedsur-
vival rates, quality of life,Mini-Mental StateExamination, and
Karnofskyperformance score. Thequality-of-life data are not
reported in this article.
Statistical Analysis
Primary and Secondary End Points
For theprimaryendpointofprogression-free survival, the cal-
culated sample size was 700 patients aimed to detect a haz-
ard ratio (HR)of0.78or less,with80%power allowing for 10%
loss to follow-up and a 2-sided α = .05. Overall survival was a
powered secondary end point in the study (80% power; HR,
0.76; 2-sided α = .05). To avoid multiplicity, overall survival
was to be tested statistically only if the primary end point of
the study was met.
To allow for 2 analyses in the trial, the final type I error of
0.05 was split between the interim and final analyses based
on a standardα spending function (Lan andDeMets23,24). The
primary end point at the final analysis would be achieved if
progression-free survival was significantly longer in the
TTFields plus temozolomide group using a stratified log-
rank test (stratified by the randomization strata) with an α of
.046 (an α of 0.014 was spent on the interim analysis).
The secondary end point would be achieved at the final
analysis ifoverallsurvivalwassignificantlylongerintheTTFields
plus temozolomidegroupusingastratified log-ranktestwithan
α of .048 (an α of .006was spent on the interim analysis).
Missing Data
For theanalysisofprogression-free survivalpatientswerecen-
sored forprogressionwhen treatmentwas changedbeforeevi-
dence of progression (at the date of treatment change), at the
date of their lastMRI if lost to followup, or upon reaching the
cutoffdatewithoutprogression.For theanalysisofoverall sur-
vival, patients without a known date of death were censored
at the last known date they were documented to be alive.
Exploratory End Points
Theexploratoryendpointsofannual survival ratesandtherate
of progression-free survival at 6 months were compared be-
tween groups using a 1-sided Z distribution of the Kaplan-
Meier estimates of the survival rates at thedefined timepoint.
In addition, the Cox proportional hazards model was used to
analyzebothprogression-freesurvivalandoverall survivalcon-
trolling for treatment group, age, sex,MGMTmethylation sta-
tus (as determined by the central laboratory), tumor location
in thebrain, andcountryof residence (UnitedStatesvsall other
countries). The threshold for significant interactions in the
model was specified at an α of .05.
Post Hoc Analysis
Post hoc analyses of prespecified subgroups (MGMT pro-
motermethylation status, extent of resection (complete, par-
tial resection, or biopsy), age (continuous), performance sta-
tus (90-100vs≤80), sex, andgeographic region (UnitedStates
vs the rest of the world) was performed using a multivariate
analysis testing thedifferencebetweentreatmentgroupswhile
controlling for the other prognostic factors.
Analysis of Adverse Events and Tolerability
Differences in the incidenceof adverseeventsbetweengroups
was tested using a χ2 test at an α of .05. The incidence of ad-
verse eventswas also comparedbetweengroups afternormal-
izingthe incidencetotheaveragetreatmentdurationpergroup.
Differences in the time to decline in Karnofsky performance
score andMini-Mental State Examinationwere tested using a
log-rank test at an α of .05. All analyseswere performedusing
SAS version 9.4.
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Results
Study Participants
Four hundred and sixty-six patients were randomized to re-
ceive TTFields plus temozolomide and 229 to receive temo-
zolomidealone (Figure 1). Patientbaselinecharacteristicswere
balanced between the 2 groups (Table 1). Themedian agewas
56 years (interquartile range [IQR], 48-63 years), 68% were
men, and median Karnofsky performance score was 90%.
Eighty-ninepercentofpatientswerewhite, and49%of thepa-
tients were treated in the United States.
Fifty-four percent had undergone a gross total resection
(>95%of the tumor removed; as assessed and reported by the
surgeon), 13% of patients had a diagnostic biopsy only. Histo-
logical slides for central pathology review were available for
Table 1. Patient and Treatment Characteristics
Characteristics
No. (%) of Patients
TTFields +
Temozolomide
(n = 466)
Temozolomide
Alone
(n = 229)
Age, y
Median (range) 56.0 (19-83) 57.0 (19-80)
≥65 89 (19) 45 (20)
<65 377 (81) 184 (80)
Karnofsky performance scorea
Median (range) 90.0 (60-100) 90.0 (70-100)
90-100 308 (66) 149 (65)
≤80 154 (33) 74 (32)
Missing 4 (1) 6 (3)
Sex
Men 316 (68) 157 (69)
Women 150 (32) 72 (31)
Region
United States 221 (47) 118 (52)
Outside the United States 245 (53) 111 (48)
Race/ethnicity
White 416 (89) 201 (88)
African American 3 (1) 1 (<1)
Asian 27 (6) 19 (8)
Hispanic 18 (4) 7 (3)
American Indian 1 (<1) 1 (<1)
Antiepileptic drug use at baseline 205 (44) 95 (41)
Corticosteroid use at baseline 135 (29) 64 (28)
Mini-Mental State Examination scoreb
27-30 356 (76) 160 (70)
≤26 88 (19) 48 (21)
Missing 22 (5) 21 (9)
Extent of resection
Biopsy 60 (13) 29 (13)
Partial resection 157 (34) 77 (33)
Gross total resection 249 (53) 123 (54)
MGMT promotor region methylation status
Tissue available and tested 386 (83) 185 (81)
Methylated 137 (36) 77 (42)
Unmethylated 209 (54) 95 (51)
Invalid 40 (10) 13 (7)
Slides available for central pathology review 296 (64) 138 (60)
Confirmed glioblastoma 285 (96) 134 (97)
WHO grade II or III glioma 4 (1) 2 (1)
Insufficient quality for diagnosis 7 (2) 2 (1)
IDH1-R132H status
Tissue available and tested 260 (56) 119 (52)
Mutated 19 (7) 6 (5)
Negative test results 240 (92) 113 (95)
Invalid 1 (<1)
EGFR status
Tissue available and tested 252 (54) 112 (49)
Amplified 102 (41) 43 (38)
Not amplified 147 (58) 68 (61)
Invalid 3 (1) 1 (1)
Tumor tissue chromosomes 1p and 19q
Tissue available and tested 259 (56) 112 (49)
Codeletion 2 (1)
Loss 1p only 4 (2) 1 (1)
Loss 19q only 3 (1) 3 (3)
Retained 239 (92) 102 (91)
Invalid 11 (4) 6 (5)
(continued)
Table 1. Patient and Treatment Characteristics (continued)
Characteristics
No. (%) of Patients
TTFields +
Temozolomide
(n = 466)
Temozolomide
Alone
(n = 229)
Tumor positionc
Corpus callosum 25 (5) 12 (5)
Frontal lobe 190 (41) 84 (37)
Occipital lobe 58 (12) 27 (12)
Parietal lobe 146 (31) 89 (39)
Temporal lobe 191 (41) 90 (40)
Missing 3 (1) 3 (1)
Tumor locationc
Left hemisphere 214 (46) 99 (43)
Right hemisphere 249 (53) 127 (55)
Both hemispheres 4 (1) 2 (1)
Corpus callosum 15 (3) 9 (4)
Missing 1 (<1) 1 (<1)
Treatment delivery
Completed standard radiation therapy
57-63 Gy 422 (91) 212 (93)
<57 Gy 21 (5) 11 (5)
>63 Gy 18 (4) 3 (1)
Dose not reported 5 (1) 3 (1)
Concomitant radiation therapy
and temozolomide
Yes 433 (93) 212 (93)
No record available 33 (7) 17 (7)
Time from last day of radiation
treatment to randomization,
median (range), d
37 (15-128) 36 (15-70)
Time from initial diagnosis to
randomization, median (range), mo
3.8
(1.7-6.2)
3.7
(1.4-6.3)
Temozolomide cycles, median (range) 6 (0-51) 5 (0-33)
Tumor-treating fields therapy
Duration, median (range), mo 8.2 (0-82)
≥18 h/d (first 3 mo of treatment),
mean
347 (75)
Abbreviations: EGFR, epidermal growth factor receptor gene;
IDH1-R132H, socitrate dehydrogenase 1 (IDH1) R132Hmutation site;
MGMT, O6-methylguanine-DNA-methyltransferase gene;
TTFields, tumor-treating fields; WHO,World Health Organization.
a Karnofsky performance score ranges from0 to 100 in 10-point increments,
with a higher score representing better performance status.
b Scores range from 1 to 30, with a higher score representing better cognitive
function.
c Multiple positions for each patient allowed (for multifocal tumors).
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434 of 695 patients (62%). The local diagnosis of glioblas-
tomawas confirmed in 419 of 434 patients (97%). For 6 cases
WHOgrade II or III diagnosesweremade, and for the remain-
ing 9patients, the available tissue for reviewdid not allow for
a definitive diagnosis or showed no tumor, yet all these pa-
tientswere included in the intent-to-treat analysis. Tumor tis-
sue for MGMT testing was available for 82% of the patients;
of thecaseswithavalid test (518of571)41%wereMGMTmeth-
ylated (40% TTFields plus temozolomide group and 45% for
the temozolomide-only group). In 7% of tumors, expression
of the IDH1-R132H mutant was demonstrated by a positive
immunohistochemistry, EGFRwas amplified in 40%.
Tumor location (lobe, hemisphere) in the brain was also
comparable between the groups. The median time from his-
tological diagnosis to randomization was 3.8 months (range,
1.7-6.2 months) for patients in the TTFields plus temozolo-
mide group, and 3.7months (range, 1.4-6.3months) for those
in the temozolomide-only group. Median time from the end
of radiotherapy to randomizationwas 37 days in the TTFields
plus temozolomide group and 36 days in the temozolomide-
only group and occurred inmost patients after starting of the
first cycle of maintenance temozolomide. Median time from
randomization to TTFields was 5 days (IQR, 3-7 days).
Treatment Delivery
Allpatientshadcompletedradiotherapyandconcomitanttemo-
zolomideasper local practice. Themediannumberof temozo-
lomide cycles until first tumor progressionwas 6 (range, 0-51)
for theTTFieldsplustemozolomidegroupand5(range,0-33) for
thetemozolomide-onlygroup; themediandurationofTTFields
treatmentwas8.2months (range, 0-82months), 51% (n = 237)
of patients continued TTFields after the first progression.
Efficacy End points
After a median follow-up of 40 months (IQR, 34-66 months),
andaminimumfollow-upof24months, theprimaryendpoint
of median progression-free survival was 6.7 months (95% CI,
6.1-8.1 months) for patients treated with TTFields plus temo-
zolomide vs 4.0months (95%CI, 3.8-4.4months) for patients
treated with temozolomide alone, for a proportional hazard
ratio (HR) of 0.63 (95% CI, 0.52-0.76; P < .001; stratified log-
ranktest;Figure2A).For thesecondaryendpointofoverall sur-
vival, the median survival duration from randomization was
20.9 months (95% CI, 19.3-22.7 months) in the TTFields plus
temozolomidegroupvs16.0months (95%CI, 14.0-18.4months)
in the temozolomide-onlygroup,proportionalHRof0.63 (95%
CI, 0.53-0.76; P < .001; stratified log-rank test; Figure 2B).
In exploratory analyses, the percentage of patients alive
at 2 years from randomization was 43% (95% CI, 39%-48%);
at 3 years, 26% (95% CI, 22%-31%), and at 5 years, 13% (95%
CI, 9%-18%) in theTTFields plus temozolomide group and for
the temozolomide-onlygroupat2yearswas31%(95%CI,25%-
38%; P < .001); at 3 years, 16% (95% CI, 12%-23%; P = .009);
and at 5 years, 5% (95% CI, 2%-11%; P = .004). Progression-
free survival at 6months was 56% (95% CI, 51%- 61%) for pa-
tients treatedwithTTFieldsplus temozolomideand37%(95%
CI, 30%-44%) with temozolomide only (P < .001) (Table 2).
An exploratory Cox proportional hazards model adjust-
ing for Karnofsky performance score,MGMTpromotormeth-
ylation status, geographic region, age, tumor location, and
extentof resectionwereconsistentwith the findingsof thepro-
gression-free andoverall survival analyses. The following fac-
torswereassociatedwith longeroverall survival:TTFieldsplus
temozolomide treatment (HR, 0.63; 95% CI, 0.53-0.76;
P < .001), female sex (HR, 0.76, 95% CI, 0.63-0.92; P = .005),
methylated MGMT promoter (HR, 0.50; 95% CI, 0.41-0.62;
P < .001), younger age (as a continuous variable; HR, 0.978
per year; 95%CI,0.969-0.985;P < .001) andhigherKarnofsky
performance score (as a categorical variable in 10 point incre-
ments; P < .001). Patients with frontal tumors had non-
significantly longer survival (HR = 0.82,CI0.67-1.01,P = .061).
Country of treatment and extent of resection were not
Figure 2. Kaplan-Meier Survival Curves for Patients Included in the Final Analysis in the Intent-to-Treat Population
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associated with a significant difference in survival (P = .101
and P = .183, respectively).
Post Hoc Subgroup Analysis
In post hoc analyses, TTFields plus temozolomide was asso-
ciatedwith an increase in progression-free survival and over-
all survival (Figure 3; Coxproportional hazards,P < .05 for the
treatment effect within each subgroup) in all subgroups of
patients regardless of age, sex, Karnofsky performance score,
MGMT promoter methylation status, geographic region, or
extent of resection. Patients 65 years or older had shorter sur-
vival thanpatients younger than65 years. In both age groups,
TTFields plus temozolomide was associated with signifi-
cantly increased survival comparedwith temozolomidealone
for older (HR, 0.51; 95% CI, 0.33-0.77) and younger patients
(HR, 0.67; 95% CI, 0.55-0.82; Figure 4A and Figure 4B).
Table 2. Summary of Study End Pointsa
TTFields +
Temozolomide
(n = 466)
Temozolomide
Alone
(n = 229)
Between-Group
Differences
Progression-free survival
Primary end point, median (95% CI), mo 6.7 (6.1-8.1) 4.0 (3.8-4.4) 2.7 (2.1-4.2)
Overall survival
Secondary end point, median (95% CI), mo 20.9 (19.3-22.7) 16.0 (14.0-18.4) 4.9 (2.3-7.9)
Exploratory end points, % (95% CI
Progression-free 6-mo survival rate 56 (51-61) 37 (30-44) 19 (15-23)
Annual survival rates, y
1 73 (69-77) 65 (59-72) 18 (10-25)
2 43 (39-48) 31 (25-38) 12 (4-18)
3 26 (22-31) 16 (12-23) 10 (3-17)
4 20 (16-25) 8 (4-14) 12 (5-19)
5 13 (9-18) 5 (2-11) 8 (2-14)
Abbreviation:
TTFields, tumor-treating fields.
a Survival rates are actuarial estimates
according to the Kaplan-Meier
method.
Figure 3. Overall Survival for Each Prognostic Patient Subgroup of Patients TreatedWith Tumor-Treating Fields Plus Temozolomide
vs Temozolomide Alone
Favors
TTFields +
Temozolomide
Favors
Temozolomide
Alone
101.00.1
Hazard Ratio (95% CI)
TTFields +
Temozolomide
No. of
Patients
No. (%)
Alive at End
of Study
Temozolomide
Alone
No. of
Patients
No. (%)
Alive at End
of Study
Median Survival (IQR), mo
TTFields +
Temozolomide
Temozolomide
AloneSubgroup
MGMT promoter region methylation status
Hazard Ratio
(95% CI)
209 9518 (9) 3 (3) 16.9 (9.7-28.2) 14.7 (9.8-24.8)Unmethylated 0.66 (0.49-0.85)
137 7726 (19) 9 (12) 31.6 (21.1-48.5) 21.2 (12.3-37.9)Methylated 0.62 (0.44-0.88)
Age, y
377 18447 (12) 14 (8) 21.6 (12.0-39.4) 17.3 (10.6-29.3)<65 0.69 (0.57-0.85)
89 4510 (11) 2 (4) 17.4 (9.0-31.5) 13.7 (7.6-24.8)≥65 0.51 (0.33-0.77)
Karnofsky performance score
308 14939 (13) 11 (7) 23.3 (13.5-41.9) 17.8 (11.9-29.3)90-100 0.70 (0.56-0.87)
154 7416 (10) 5 (7) 14.9 (8.4-29.8) 11.0 (5.7-23.3)≤80 0.58 (0.45-0.88)
Sex
150 7221 (14) 6 (8) 24.6 (14.4-48.2) 18.5 (11.3-27.6)Women 0.64 (0.56-0.87)
466 22957 (12) 16 (7) 20.9 (11.3-37.6) 16.0 (9.3-27.5)Overall 0.63 (0.53-0.76)
316 15736 (11) 10 (6) 19.1 (10.0-34.1) 15.5 (8.4-26.5)Men 0.63 (0.45-0.88)
Region
245 11132 (13) 9 (8) 20.1 (11.3-32.2) 15.5 (9.3-25.6)Outside United States 0.66 (0.51-0.85)
221 11825 (11) 7 (6) 22.0 (11.3-48.2) 17.1 (9.8-29.2)United States 0.63 (0.49-0.82)
Resection
60 295 (8) 0 (0) 16.5 (9.0-24.7) 11.6 (7.1-18.1)Biopsy 0.50 (0.30-0.84)
157 7720 (13) 3 (4) 21.4 (9.9-37.6) 15.1 (7.8-23.3)Partial 0.56 (0.41-0.77)
249 12332 (13) 13 (11) 22.6 (13.4-39.8) 18.5 (12.1-31.6)Gross total 0.70 (0.54-0.91)
Data points represent Coxhazard ratios of overall survival in each subgroupof patients treatedwith tumor-treating fields (TTFields) plus temozolomide comparedwith
temozolomide alone andwere adjusted for the other subgroups. Error bars represent 95%CIs of the hazard ratios. TheKarnofsky performance score ismeasured
from0 to 100 in 10-point increments,with higher scores indicating better the patient performance status.
IQR, indicates interquartile range;MGMT, O6-methylguanine-DNAmethyltransferase promotor regionmethylation status.
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Patients with tumors that lacked MGMT promoter methyla-
tion had a significantly shorter survival than patients with
tumors with MGMT promoter methylation, although use of
TTFields with temozolomide was associated with longer
survival (HR, 0.66; 95% CI, 0.49-0.85 both in patients with
tumors that were MGMT methylated and tumors that were
unmethylated, respectively; Figure 4C and Figure 4D). In the
TTFields plus temozolomide group, 265 patients who were
treatedwith TTFields for 18 hours a day ormore (monthly av-
erage in the first 6 months of treatment) had longer survival
than 185patients treated less than 18hoursaday (22.6months,
95%CI, 19.7-25.1monthsvs 19.1months,95%CI, 16.5-21.9;HR,
0.65; 95% CI, 0.49-0.85; P = .009).
Adverse Events and Tolerability
TheadditionofTTFields to temozolomide therapywasnot as-
sociated with any significant increase in rates of systemic ad-
verseeventscomparedwith temozolomide therapyalone (48%
vs44%,respectively;P = .58;Table3), andtheoverall incidence,
distribution,andseverityofadverseeventswerenotstatistically
different inpatients in the2 treatmentgroups.Thenumerically
higher incidence of some adverse events in the TTFields plus
temozolomidegroupwas a reflectionof the longerdurationof
temozolomidetreatmentinthisgroupduetodelayedoccurrence
ofprogression.Whenadverseevent incidencenormalizedtodu-
rationoftreatmentwasanalyzed,thesedifferencesdisappeared.
Theonlyexceptionwasahigher incidenceof localizedskintoxic
effects (medicaldevice site reactionbeneath the transducer ar-
rays) inpatients treatedwithTTFieldsplus temozolomide;mild
tomoderateskin irritationwasobserved in52%ofpatients, and
severe (grade3) skin involvementoccurred in2%.Anxiety, con-
fusion, insomnia,andheadacheswhichwerereportedmorefre-
quently (statistically nonsignificant) in patients treated with
TTFields at the interim analysis were not seen in the final ad-
verse event analysis of the trial. The incidence of seizureswas
identical in the 2 groups.
To estimate tolerability, prespecified exploratory analy-
ses of the association of TTFields device use with patients’
Figure 4. Overall Survival by Patient Age and byMGMT Promotor RegionMethylation Status
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activities of daily life and cognitionwere performedusing the
Karnofsky performance score and the Mini-Mental State
Examination. Time to a sustained6-point decline in theMini-
Mental StateExamination scorewas significantly longer in the
TTFields plus temozolomide group than the temozolomide-
alone group (16.7 months, 95% CI, 14.7-19.0 months vs 14.2
months, 95%CI, 12.7-17.0months, respectively;HR,0.79;95%
CI, 0.66- 0.95;P = .01). Time to a sustained 10-point decrease
in Karnofsky performance score was also significantly longer
in the TTFields plus temozolomide group than in the temo-
zolomide-alone group (5.5 months;, 95% CI, 5.0-6.3 months
vs 3.9months; 95%CI, 3.1-5.2months, respectively;HR,0.80;
95% CI, 0.67-0.95; P = .009).
Discussion
In the final analysis of this randomized phase 3 trial, the ad-
dition of the TTFields treatment to standard temozolomide
maintenance therapy, compared with standard temozolo-
mide maintenance therapy alone, resulted in increased pro-
gression-free survival and overall survival in patients with
newlydiagnosedglioblastoma.After amedian follow-upof40
months, the addition of TTFields to temozolomide, com-
pared with temozolomide alone, resulted in longer median
progression-free survival from the timeof randomization, 6.7
monthsvs4.0monthsand longermedianoverall survival from
randomization, 20.9 months vs 16.0 months, respectively.
These findings are consistent with the preliminary results re-
ported based on a planned interim analysis of the first 315
patients enrolled, after a median follow-up of 38 months, in
which median progression-free survival in the intent-to-
treat population was 7.1 months (95% CI, 5.9-8.2 months) in
the TTFields plus temozolomide group (210 patients
analyzed) and 4.0 months (95% CI, 3.3-5.2 months) in the
temozolomide-alone group (105 patients analyzed).
In the current study, exploratory end points were consis-
tentwith the primary and secondary endpoints in this trial. In
aposthocanalysistheeffectofTTFieldswasobservedinallclini-
cal andmolecular subgroups, includingpatientsolder thanage
65 years and patients withMGMT unmethylated tumors.
To assess whether the improved outcomemay have been
related toother factors than theTTFields therapy thedatawere
scrutinized for possible imbalances, unexpected poor perfor-
mance of the control group, or differences in supportive care
administeredtopatientsbetweenthe2groups.Bothclinical fac-
tors and molecular tumor characteristics were well balanced
andcomparablebetween the2groups.MGMTpromotermeth-
ylation, the strongest predictive factor for outcome in temozo-
lomide-treated patients,25 was more prevalent in the control
group(45%vs40%ofsampleswithavalid result).Patientswith
early tumor progression occurring during the first 3 months
after diagnosis were not included in this trial, and so the ran-
domized patient population had a better prognosis, for both
groups, compared with other trials that had randomized pa-
tientsbeforeradiationtherapy.Thereportedsurvival timeswere
measured from randomization, not from diagnosis, so for an
estimationof theoverall outcome3.8months shouldbeadded
inbothgroups.TheRTOG0525/Intergroupstudy,whichevalu-
ateddose-dense temozolomide, also randomizedpatientsonly
after completion of radiochemotherapy.8 Outcome of the con-
trol group in thecurrent studyandof theRTOGstudywerevery
similar, and inbothstudies, themediansurvival fromrandom-
ization was 16months.
In this trial, the rates of systemic adverse effectswere not
significantly different in the 2 treatment groups. The occur-
renceofmild tomoderate skin irritation related to reactionbe-
neath the transducerarraysof thedeviceoccurred inmore than
half of patients in the TTFields plus temozolomide group.
These findings are in contrast to the more than 23
randomized trials conducted over the last decade that have
evaluated novel agents or intensified treatment strategies
Table 3. Adverse Events by Body System and Severity (≥5% Incidence in Any Group)
Grade 3-4 Events,
No. (%) of Patients
TTFields +
Temozolomide
(n = 456)
Temozolomide
Alone
(n = 229)
≥1 Adverse event 218 (48) 94 (44)
Blood and lymphatic system disordersa 59 (13) 23 (11)
Thrombocytopenia 39 (9) 11 (5)
Gastrointestinal disorders 23 (5) 8 (4)
Asthenia, fatigue, and gait disturbance 42 (9) 13 (6)
Infections 32 (7) 10 (5)
Injury, poisoning, and procedural complications
(falls and medical device site reaction)
24 (5) 7 (3)
Metabolism and nutrition disorders (anorexia, dehydration,
and hyperglycemia)
16 (4) 10 (5)
Musculoskeletal and connective tissue disorders 21 (5) 9 (4)
Nervous system disorders 109 (24) 43 (20)
Seizures 26 (6) 13 (6)
Respiratory, thoracic and mediastinal disorders (pulmonary embolism,
dyspnea, and aspiration pneumonia)
24 (5) 11 (5)
Abbreviation:
TTFields, tumor-treating fields.
a The numerically slightly higher
incidence of hematological toxicity,
fatigue, and some other adverse
effects are due to the longer
treatment duration and observation
time in the experimental group. The
differences disappear when data are
normalized to treatment duration.
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(eg, dose-dense temozolomide, cilengitide, nimotuzumab,
bevacizumab, and rindopepimut3,5,8,26) for treatment of pa-
tients with newly diagnosed glioblastoma and have failed to
demonstrate improved survival. Innovative treatments for
glioblastoma are needed.
Limitations
This study has several limitations. First, the current trial was
open-label because it was considered practically unfeasible
(heat and easy measure of current associated with TTFields)
and ethically unacceptable to expose patients to a sham
device. Although a placebo effect may affect subjective end
points like quality of life or even progression-free survival by
influencing the frequency of imaging and its interpretation,
in the current trial a consistent benefit was observed in
progression-free survival as assessed by blinded central radi-
ology review, as well as in the gold standard of objective out-
come, overall survival. Second, delivery of TTFields therapy
requires the patient to continuously carry a device on a
shaved scalp and may create burdens for patients. Neverthe-
less, the majority of patients were able to handle the device
independently or with some help from a caregiver. The fact
that 75% of patients achieved treatment adherence of 75% or
more (ie, using the device for ≥18 hours per day) indicated
good tolerability. The effects of the TTFields treatment and
the need for continuous use of the device on quality of life
will be reported separately.
Conclusions
In the final analysis of this randomized clinical trial of
patients with glioblastoma who had received standard radio-
chemotherapy, the addition of TTFields to maintenance
temozolomide chemotherapy vs maintenance temozolo-
mide alone, resulted in statistically significant improvement
in progression-free survival and overall survival. These
results are consistent with the previous interim analysis.
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